Why has the NIB share price leapt 14% in a month?

NIB shares have been in fine form recently…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The NIB Holdings Limited (ASX: NHF) share price has been a strong performer in recent weeks.

Since this time last month, the private health insurer's shares have risen by almost 14% to $7.89.

This leaves the NIB share price trading within a whisker of its 52-week high of $8.20.

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face.

Image source: Getty Images

Why is the NIB share price on form?

Investors have been buying the company's shares since the release of its full year results last month.

For the 12 months ended 30 June, NIB reported a 7.2% increase in revenue to $2.8 billion. This was driven by the company's Australian Residents Health Insurance (ARHI) business, which grew well ahead of industry expectations thanks to strong premium revenue growth. This was despite the company deferring the 2022 annual premium increase.

And while NIB reported a 16.6% decline in net profit to $133.8 million, this reflects investment losses of $81.8 million and was still slightly ahead of consensus estimates.

Also giving its shares a lift was management's outlook commentary. It appears cautiously optimistic on FY 2023. It said:

While wary of broader macro-economic conditions and ongoing COVID-19 threats, nib expects favourable market conditions for each of its businesses in FY23 and beyond.

Can its shares keep rising?

Unfortunately, most brokers appear to believe the NIB share price has now peaked.

The most bullish broker I'm aware of is Morgans with its hold rating and $8.36 price target. This implies potential upside of 6% for investors from current levels.

Its analysts are also expecting its shares to provide a fully franked 3.5% dividend yield in FY 2023. This stretches the total potential return to almost 10%, which isn't bad for a hold rating.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended NIB Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Stethoscope with a piggy bank in the middle.
Healthcare Shares

3 reasons why this ASX healthcare share price is a buy

This ASX healthcare share has a very positive outlook.

Read more »

An older woman tries to listen by cupping her ear.
Healthcare Shares

How many Cochlear shares do I need to buy for $10,000 of passive income?

The dividend maths on this fallen ASX healthcare heavyweight.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Broker Notes

Are Telix shares a buy, hold or sell following results?

This exciting healthcare stock is tipped to keep rising.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Up 53%, here's why this ASX All Ords healthcare share is tipped for more outperformance

A leading fund manager forecasts more outperformance from this surging ASX healthcare share.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Up 79% since February, why are Telix shares jumping higher again on Tuesday?

Investors are piling into Telix shares in Tuesday’s slumping market. But why?

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Top 3 ASX healthcare stocks to watch

Three beaten-down ASX healthcare stocks staging a strong comeback.

Read more »

A man in trendy clothing sits on a bench in a shopping mall looking at his phone with interest and a surprised look on his face.
Healthcare Shares

Telix Pharmaceuticals: Q2 2026 revenue jumps 21%

Telix Pharmaceuticals also provided an update on its key clinical pipeline and new partnerships.

Read more »

Stressed, unhappy, and tired scientist with a headache working on a computer in a lab.
Healthcare Shares

Down 50%+: Are these ASX healthcare shares finally worth buying?

Both healthcare leaders face setbacks, but their competitive advantages remain intact.

Read more »